NCT06744556View on ClinicalTrials.gov

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
AML
Interventions
DRUG

daunorubicin

Used in combination with cytarabine and venetoclax for induction therapy in DAV.

DRUG

Venetoclax

Used in combination with cytarabine and daunorubicin for induction therapy in DAV.

DRUG

cytarabine

Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.

DRUG

azacitidine

Used in combination with venetoclax for maintenance therapy.

DRUG

Homoharringtonine

Used in combination with cytarabine and venetoclax for induction therapy in HAV.

DRUG

Idarubicin

Used in combination with cytarabine and venetoclax for induction therapy in IAV.

Trial Locations (1)

300020

RECRUITING

Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER